RhumbLine Advisers
IMMX icon

RhumbLine Advisers’s Immix Biopharma IMMX Stock Holding History

RhumbLine Advisers’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Buy
+50,944
New +$473K ﹤0.01% 2736

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's IMMX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Immix Biopharma (IMMX) in Q2 2026: 50,944 shares worth $525K. The stake represents ﹤0.01% of the portfolio and ranks #2736 among its holdings.

109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • RhumbLine Advisers held 50,944 shares of Immix Biopharma worth $525K as of Q2 2026.
  • Immix Biopharma was a new RhumbLine Advisers position in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2736 holding.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.